https://doi.org/10.4081/reumatismo.2020.1297
Case report of polymyalgia rheumatica in a male patient with three different neoplasms treated with pembrolizumab
Submitted: 11 May 2020
Accepted: 18 July 2020
Published: 19 November 2020
Accepted: 18 July 2020
Abstract Views: 1045
PDF: 641
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
In this manuscript we aim to describe a particular case of a 63 years-old man who developed three different malignancies (one was a rare case of breast cancer) among nearly five years. In particular, for the diagnosis of melanoma, he was treated with pembrolizumab, a PD-1 inhibitor. After few months of treatment with pembrolizumab, the patient reported the onset of musculoskeletal symptoms such as inflammatory pain at the shoulders and morning stiffness, with raised CRP and ESR and imaging evidence of bursitis and tenosynovitis. A polymyalgia-like syndrome was diagnosed. Understanding if these manifestations are linked to the use of pembrolizumab or to a paraneoplastic syndrome, and how to manage the patient, was the real challenge.
How to Cite
Perrotta, F., Scriffignano, S., Fatica, M., Specchia, M., & Lubrano, E. (2020). Case report of polymyalgia rheumatica in a male patient with three different neoplasms treated with pembrolizumab. Reumatismo, 72(3), 178–181. https://doi.org/10.4081/reumatismo.2020.1297
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- C. Perricone, C. Alessandri, G. Valesini, ‘ASIA’ - Autoimmune/inflammatory syndrome induced by adjuvants: even and odd , Reumatismo: Vol. 63 No. 2 (2011)
- R. Brizzolara, S. Soldano, P. Montagna, A. Sulli, B. Seriolo, B. Villaggio, P.F. Triolo, P. Clerico, L. Felli, L. Molfetta, M. Cutolo, CTLA4-Ig interferes and downregulates the proinflammatory activities of rheumatoid synovial macrophages in monoculture , Reumatismo: Vol. 63 No. 2 (2011)
- L. Cantarini, D. Rigante, M.G. Brizi, G.D. Sebastiani, O.M. Lucherini, M. Galeazzi, B. Frediani, The laboratory approach in the diagnosis of systemic autoinflammatory diseases , Reumatismo: Vol. 63 No. 2 (2011)
- N. Busso, H.-K. Ea, The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis) , Reumatismo: Vol. 63 No. 4 (2011): Special issue • Microcrystalline Arthritis
- F. Lioté, Treatment of hyperuricemia, gout and other crystalline arthritidies , Reumatismo: Vol. 63 No. 4 (2011): Special issue • Microcrystalline Arthritis
- G. Lapadula, F. Iannone, An unwelcome host in the pathogenesis of arthritides , Reumatismo: Vol. 55 No. 2 (2003)
- G. Valesini, Are there differences among anti-TNFa biological drugs? , Reumatismo: Vol. 57 No. s4 (2005)
- M. Favero, F. Schiavon, L. Riato, V. Carraro, L. Punzi, Septic arthritis: a 12 years retrospective study in a rheumatological university clinic , Reumatismo: Vol. 60 No. 4 (2008)
- A. Alunno, G. Nocentini, O. Bistoni, R. Bianchini, E. Bartoloni Bocci, C. Riccardi, R. Gerli, Glucocorticoid induced TNFR-related protein (GITR) as marker of human regulatory T cells: expansion of the GITR+CD25- cell subset in patients with systemic lupus erythematosus , Reumatismo: Vol. 62 No. 3 (2010)
- G. Pasero, P. Marson, A short history of anti-rheumatic therapy. III. Non steroidal anti-inflammatory drugs , Reumatismo: Vol. 62 No. 3 (2010)
You may also start an advanced similarity search for this article.
